Mode and site of action of therapies targeting CGRP signaling

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments current...

Descripción completa

Detalles Bibliográficos
Autores principales: Labastida-Ramírez, Alejandro, Caronna, Edoardo, Gollion, Cédric, Stanyer, Emily, Dapkute, Austeja, Braniste, Diana, Naghshineh, Hoda, Meksa, Liga, Chkhitunidze, Nino, Gudadze, Tamari, Pozo-Rosich, Patricia, Burstein, Rami, Hoffmann, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494408/
https://www.ncbi.nlm.nih.gov/pubmed/37691118
http://dx.doi.org/10.1186/s10194-023-01644-8
_version_ 1785104685206601728
author Labastida-Ramírez, Alejandro
Caronna, Edoardo
Gollion, Cédric
Stanyer, Emily
Dapkute, Austeja
Braniste, Diana
Naghshineh, Hoda
Meksa, Liga
Chkhitunidze, Nino
Gudadze, Tamari
Pozo-Rosich, Patricia
Burstein, Rami
Hoffmann, Jan
author_facet Labastida-Ramírez, Alejandro
Caronna, Edoardo
Gollion, Cédric
Stanyer, Emily
Dapkute, Austeja
Braniste, Diana
Naghshineh, Hoda
Meksa, Liga
Chkhitunidze, Nino
Gudadze, Tamari
Pozo-Rosich, Patricia
Burstein, Rami
Hoffmann, Jan
author_sort Labastida-Ramírez, Alejandro
collection PubMed
description Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.
format Online
Article
Text
id pubmed-10494408
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-104944082023-09-12 Mode and site of action of therapies targeting CGRP signaling Labastida-Ramírez, Alejandro Caronna, Edoardo Gollion, Cédric Stanyer, Emily Dapkute, Austeja Braniste, Diana Naghshineh, Hoda Meksa, Liga Chkhitunidze, Nino Gudadze, Tamari Pozo-Rosich, Patricia Burstein, Rami Hoffmann, Jan J Headache Pain Review Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed. Springer Milan 2023-09-11 /pmc/articles/PMC10494408/ /pubmed/37691118 http://dx.doi.org/10.1186/s10194-023-01644-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Labastida-Ramírez, Alejandro
Caronna, Edoardo
Gollion, Cédric
Stanyer, Emily
Dapkute, Austeja
Braniste, Diana
Naghshineh, Hoda
Meksa, Liga
Chkhitunidze, Nino
Gudadze, Tamari
Pozo-Rosich, Patricia
Burstein, Rami
Hoffmann, Jan
Mode and site of action of therapies targeting CGRP signaling
title Mode and site of action of therapies targeting CGRP signaling
title_full Mode and site of action of therapies targeting CGRP signaling
title_fullStr Mode and site of action of therapies targeting CGRP signaling
title_full_unstemmed Mode and site of action of therapies targeting CGRP signaling
title_short Mode and site of action of therapies targeting CGRP signaling
title_sort mode and site of action of therapies targeting cgrp signaling
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494408/
https://www.ncbi.nlm.nih.gov/pubmed/37691118
http://dx.doi.org/10.1186/s10194-023-01644-8
work_keys_str_mv AT labastidaramirezalejandro modeandsiteofactionoftherapiestargetingcgrpsignaling
AT caronnaedoardo modeandsiteofactionoftherapiestargetingcgrpsignaling
AT gollioncedric modeandsiteofactionoftherapiestargetingcgrpsignaling
AT stanyeremily modeandsiteofactionoftherapiestargetingcgrpsignaling
AT dapkuteausteja modeandsiteofactionoftherapiestargetingcgrpsignaling
AT branistediana modeandsiteofactionoftherapiestargetingcgrpsignaling
AT naghshinehhoda modeandsiteofactionoftherapiestargetingcgrpsignaling
AT meksaliga modeandsiteofactionoftherapiestargetingcgrpsignaling
AT chkhitunidzenino modeandsiteofactionoftherapiestargetingcgrpsignaling
AT gudadzetamari modeandsiteofactionoftherapiestargetingcgrpsignaling
AT pozorosichpatricia modeandsiteofactionoftherapiestargetingcgrpsignaling
AT bursteinrami modeandsiteofactionoftherapiestargetingcgrpsignaling
AT hoffmannjan modeandsiteofactionoftherapiestargetingcgrpsignaling

Ejemplares similares